Exacerbation of acquired perforating dermatosis following SARS‐CoV‐2 vaccination
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.19137 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Nadia Sciamarrelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: COVID-19, Skin Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
- Department of Oncology, Pathology Unit, University of Turin, Turin, Italy.
ORCID-Profile: Nadia Sciamarrelli, Niccolò Siliquini, Luca Mastorino, Simone Ribero, Pietro Quaglino
Zitieren
APA
Sciamarrelli, N., Siliquini, N., Mastorino, L., Senetta, R., Dapavo, P., Ribero, S., & Quaglino, P. (2023). Exacerbation of acquired perforating dermatosis following SARS‐CoV‐2 vaccination. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19137
Vancouver
Sciamarrelli N, Siliquini N, Mastorino L, Senetta R, Dapavo P, Ribero S, et al. Exacerbation of acquired perforating dermatosis following SARS‐CoV‐2 vaccination. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19137
BibTeX
@article{Sciamarrelli2023,
author = {Sciamarrelli, Nadia and Siliquini, Niccolò and Mastorino, Luca and Senetta, Rebecca and Dapavo, Paolo and Ribero, Simone and Quaglino, Pietro},
title = {Exacerbation of acquired perforating dermatosis following SARS‐CoV‐2 vaccination},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.19137}
}
EUVIMED